Overview

TYK2 Inhibition in Paradoxical Psoriasis

Status:
TERMINATED
Trial end date:
2025-03-20
Target enrollment:
Participant gender:
Summary
Paradoxical psoriasis is a side effect of a biological treatment (anti-tumor necrosis factor agent, short called anti-TNF) that is used to treat diseases of the skin, the intestine or the joints. If paradoxical psoriasis occurs, the anti-TNF-treatment often needs to be stopped and so far, no specific treatment for paradoxical psoriasis exists. This research project aims to study whether the efficacy of the drug 'Deucravacitinib' 6mg, a tablet taken by mouth once a day is superior compared to taking a placebo in treating paradoxical psoriasis.
Phase:
PHASE2
Details
Lead Sponsor:
Prof Curdin Conrad
Collaborator:
Centre Hospitalier Universitaire Vaudois
Treatments:
deucravacitinib